To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers
The purpose of study is to compare the safety and pharmacokinetics of PT105 with PT105R in healthy postmenopausal female volunteers
Prostate Cancer
DRUG: leuprorelin acetate 3.75mg
AUC7-t of Leuprolide, AUC7-t, 0h, 0.5, 1, 2, 4, 8, 12, 24, 72, 168, 240, 336, 504, 672, 840, 1008 hr|AUCt of Leuprolide, AUCt, 0h, 0.5, 1, 2, 4, 8, 12, 24, 72, 168, 240, 336, 504, 672, 840, 1008 hr|AUCinf of Leuprolide, AUCinf, 0h, 0.5, 1, 2, 4, 8, 12, 24, 72, 168, 240, 336, 504, 672, 840, 1008 hr|Cmax of Leuprolide, Cmax, 0h, 0.5, 1, 2, 4, 8, 12, 24, 72, 168, 240, 336, 504, 672, 840, 1008 hr
Tmax of Leuprolide, Tmax, 0h, 0.5, 1, 2, 4, 8, 12, 24, 72, 168, 240, 336, 504, 672, 840, 1008 hr|t1/2 of Leuprolide, t1/2, 0h, 0.5, 1, 2, 4, 8, 12, 24, 72, 168, 240, 336, 504, 672, 840, 1008 hr
The purpose of study is to confirm the safety and pharmacokinetics of PT105 in healthy postmenopausal female volunteers